Bio-Raid

banner

Time of issue:2019-07-09 00:00:00

 

这是描述信息
/
Technology
All categories

Technology

  • Categories:Our science
  • Time of issue:2019-05-29 00:00:00
  • Views:0
Description:
Description:
Information
1.More than 500 cases of exploratory clinical research have been completed in hematological tumor, and the clinical efficacy of The CAR-T products of Bio-raid is better than international.
(1) CD19+CD22 CAR-T cell sequential therapy
The first CD19+CD22 CAR-T cell sequential therapy can target CD19 and CD22, respectively, to avoid the recurrence caused by the escape mechanism of cancer cells under the pressure of single-target CAR-T cell therapy. The clinical efficacy is better than international.
(2) CD19/22 Dual-CAR-T
CD19/22 Dual-CAR-T treatment of diffuse large B lymphoma whi